Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Owen

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Bioorganic & Medicinal Chemistry Letters|December 11, 2007
Development of CXCR3 antagonists. Part 4: discovery of 2-amino-(4-tropinyl)quinolinesRoland L Knight, Daniel R Allen, Helen L Birch, et al.
Angiogenesis|March 11, 2016
The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growthDonald T Yapp, May Q Wong, Alastair H Kyle, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 1, 2007
CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient miceEva J A van Wanrooij, Saskia C A de Jager, Thomas van Es, et al.
Bioorganic & Medicinal Chemistry Letters|November 23, 2007
Development of CXCR3 antagonists. Part 3: Tropenyl and homotropenyl-piperidine urea derivativesRobert J Watson, Daniel R Allen, Helen L Birch, et al.
Plos One|December 22, 2016
A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development PropertiesAndrew C Nyborg, Chris Ward, Anna Zacco, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Bioorganic & Medicinal Chemistry Letters|December 11, 2007
Development of CXCR3 antagonists. Part 4: discovery of 2-amino-(4-tropinyl)quinolinesRoland L Knight, Daniel R Allen, Helen L Birch, et al.
Angiogenesis|March 11, 2016
The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growthDonald T Yapp, May Q Wong, Alastair H Kyle, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 1, 2007
CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient miceEva J A van Wanrooij, Saskia C A de Jager, Thomas van Es, et al.
Bioorganic & Medicinal Chemistry Letters|November 23, 2007
Development of CXCR3 antagonists. Part 3: Tropenyl and homotropenyl-piperidine urea derivativesRobert J Watson, Daniel R Allen, Helen L Birch, et al.
Plos One|December 22, 2016
A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development PropertiesAndrew C Nyborg, Chris Ward, Anna Zacco, et al.
Pageof 4